What happened with VSTM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Verastem’s commercial business centers on AVMAPKI FAKZYNJA CO-PACK, which packages avutometinib capsules and defactinib tablets together as an oral cancer treatment. It sells the product to specialty pharmacies and distributors, which supply patients directly or through healthcare providers. The treatment is commercially available only in the United States, where its FDA-approved use is for adults with recurrent low-grade serous ovarian cancer carrying a KRAS mutation who have already received systemic therapy. Revenue depends heavily on this one product, physician adoption and insurers’ and other payers’ willingness to cover and reimburse treatment.
Verastem licenses avutometinib from Chugai and defactinib from Pfizer, paying royalties on sales and bearing development and commercialization costs. It relies entirely on outside manufacturers for supply, without backup arrangements throughout the supply chain. Keeping its commercial business operating also depends on maintaining those licenses and the product’s accelerated FDA approval. That approval requires follow-up trials to confirm clinical benefit; the FDA can withdraw it if the required trials are not pursued diligently or fail to confirm benefit.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Verastem’s results hinge on its U.S. co-pack launch using Chugai-licensed avutometinib and Pfizer-licensed defactinib, alongside development of its GenFleet-licensed KRAS program.
Revolution Medicines competes with Verastem’s licensed KRAS program by developing drugs targeting RAS G12D and a broader range of RAS-driven cancers. Watch clinical updates on zoldonrasib and daraxonrasib for the competing treatment approaches Verastem faces.
Erasca’s drugs targeting a broad range of KRAS and RAS forms overlap with Verastem’s KRAS and RAF/MEK cancer-treatment programs. Its clinical updates on ERAS-4001 and ERAS-0015 matter more to this comparison than product sales: Erasca had no approved products or revenue at the end of 2025.
Novartis overlaps with the treatment market for Verastem’s avutometinib-defactinib co-pack: its trametinib, a MEK inhibitor, is used to treat recurrent low-grade serous ovarian cancer.
Verastem depends on Pfizer’s permission to develop and sell defactinib, one component of its commercial co-pack, and pays Pfizer approval milestones and royalties on net sales. Verastem paid $7.5 million on approval in 2025 and expected to pay another $8 million on the approval’s first anniversary in 2026; growing co-pack sales also bring royalty payments to Pfizer.
Progress in treating KRAS-mutated cancers matters to both Verastem’s KRAS inhibitors and Elicio Therapeutics’ cancer vaccines, though they take different approaches. Watch Elicio’s Phase 2 study of ELI-002 7P in KRAS-mutated pancreatic ductal adenocarcinoma for clinical evidence from the vaccine approach, rather than evidence about Verastem’s drugs themselves.
Novartis AG earningsNVS
Novartis’s report will offer a read on demand for trametinib in recurrent low-grade serous ovarian cancer, the treatment market where Verastem’s co-pack must win physician and patient acceptance.
Look for what Novartis says about use and demand for trametinib in recurrent low-grade serous ovarian cancer. Strong demand would point to an active treatment market where Verastem’s co-pack must win adoption; weakening demand would suggest a softer market, but would not establish how Verastem’s drug works or sells. The report helps judge the market’s activity, not Verastem’s own performance.
Fed Interest Rate Decision
Verastem’s Fed-linked rates matter because it pays interest on notes at a rate tied to Term SOFR, so higher borrowing costs can leave less cash for developing and selling its cancer medicines.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed raises rates more than expected, higher rates may lift the SOFR-linked interest Verastem owes on its notes, leaving less cash for its drug development and U.S. commercial operations.
If it comes in below expectations
If the Fed raises rates less than expected or cuts them, lower rates may reduce the SOFR-linked interest Verastem owes on its notes, leaving more cash for drug development and U.S. commercial operations.
Verastem, Inc. earningsThis company
Verastem’s report will show whether its ovarian-cancer drug co-pack is reaching more patients through specialty pharmacies and distributors and building product revenue.
Read AVMAPKI FAKZYNJA CO-PACK product revenue alongside what Verastem says about its sales channels. Rising revenue with broader channel reach would show that more patients may be getting treatment through specialty pharmacies or healthcare entities, widening the launch’s sales base. Weak revenue or limited reach would suggest that coverage, physician adoption or patient access may still be constraining sales. The question is whether this product can build a broader U.S. business beyond its early launch.
Pfizer Inc. earningsPFE
Pfizer’s report matters because Verastem’s co-pack contains Pfizer-licensed defactinib, and sales of the co-pack generate royalty payments to Pfizer.
Watch for Pfizer disclosures about the defactinib license or related product sales, and read them alongside Verastem’s co-pack sales. Continued collaboration and sales would support Verastem’s ability to keep selling a product that relies on this licensed component, while growing sales also mean more royalties paid to Pfizer. A disruption to the relationship or related sales could put Verastem’s supply and commercial path at risk. Pfizer’s overall results alone do not prove how this specific arrangement is doing; the key is whether the license and related sales continue.
